181 related articles for article (PubMed ID: 28228864)
1. Innovative payer engagement strategies: will the convergence lead to better value creation in personalized medicine?
Akhmetov I; Bubnov RV
EPMA J; 2017 Dec; 8(1):5-15. PubMed ID: 28228864
[TBL] [Abstract][Full Text] [Related]
2. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2016; (43):9-61. PubMed ID: 27491172
[TBL] [Abstract][Full Text] [Related]
3. A review of international coverage and pricing strategies for personalized medicine and orphan drugs.
Degtiar I
Health Policy; 2017 Dec; 121(12):1240-1248. PubMed ID: 29033060
[TBL] [Abstract][Full Text] [Related]
4. Strengthening Multipayer Collaboration: Lessons From the Comprehensive Primary Care Initiative.
Anglin G; Tu HA; Liao K; Sessums L; Taylor EF
Milbank Q; 2017 Sep; 95(3):602-633. PubMed ID: 28895218
[TBL] [Abstract][Full Text] [Related]
5. Assessing payer perspectives on health information exchange.
Cross DA; Lin SC; Adler-Milstein J
J Am Med Inform Assoc; 2016 Mar; 23(2):297-303. PubMed ID: 26142424
[TBL] [Abstract][Full Text] [Related]
6. Companies' Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study.
Wang T; McAuslane N; Liberti L; Gardarsdottir H; Goettsch W; Leufkens H
Front Pharmacol; 2020; 11():594549. PubMed ID: 33390978
[No Abstract] [Full Text] [Related]
7. Assessing value of innovative molecular diagnostic tests in the concept of predictive, preventive, and personalized medicine.
Akhmetov I; Bubnov RV
EPMA J; 2015; 6():19. PubMed ID: 26425215
[TBL] [Abstract][Full Text] [Related]
8. Personalized medicine and the role of health economics and outcomes research: issues, applications, emerging trends, and future research.
O'Donnell JC
Value Health; 2013; 16(6 Suppl):S1-3. PubMed ID: 24034305
[TBL] [Abstract][Full Text] [Related]
9. New ways of insulin delivery.
Heinemann L
Int J Clin Pract Suppl; 2011 Feb; (170):31-46. PubMed ID: 21323811
[TBL] [Abstract][Full Text] [Related]
10. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group.
Faulkner E; Annemans L; Garrison L; Helfand M; Holtorf AP; Hornberger J; Hughes D; Li T; Malone D; Payne K; Siebert U; Towse A; Veenstra D; Watkins J;
Value Health; 2012 Dec; 15(8):1162-71. PubMed ID: 23244820
[TBL] [Abstract][Full Text] [Related]
11. Critical Care Network in the State of Qatar.
Hijjeh M; Al Shaikh L; Alinier G; Selwood D; Malmstrom F; Hassan IF
Qatar Med J; 2019; 2019(2):2. PubMed ID: 31763205
[TBL] [Abstract][Full Text] [Related]
12. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
13. Requirements for a Successful Drug Launch in Small Markets: A Pilot Study in Lebanon.
Ramadan B; Metni M; Hamadeh G; Kurdi M; Karam R
Value Health Reg Issues; 2019 Sep; 19():59-64. PubMed ID: 31078969
[TBL] [Abstract][Full Text] [Related]
14. Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience.
Dunlop WCN; Staufer A; Levy P; Edwards GJ
Health Policy; 2018 May; 122(5):528-532. PubMed ID: 29567205
[TBL] [Abstract][Full Text] [Related]
15. The inaugural Qatar Critical Care Conference with its Qatar Medical Journal Special Issue - An important milestone.
Hassan IF; Alinier G
Qatar Med J; 2019; 2019(2):1. PubMed ID: 31763204
[TBL] [Abstract][Full Text] [Related]
16. The Personalized Medicine Coalition: goals and strategies.
Abrahams E; Ginsburg GS; Silver M
Am J Pharmacogenomics; 2005; 5(6):345-55. PubMed ID: 16336000
[TBL] [Abstract][Full Text] [Related]
17. New ways of insulin delivery.
Heinemann L
Int J Clin Pract Suppl; 2010 Feb; (166):29-40. PubMed ID: 20377662
[TBL] [Abstract][Full Text] [Related]
18. [Clinical and health economic challenges of personalized medicine].
Brüggenjürgen B; Kornbluth L; Ferrara JV; Willich SN
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 May; 55(5):710-4. PubMed ID: 22526860
[TBL] [Abstract][Full Text] [Related]
19. Combating complexity: partnerships in personalized medicine.
Pothier K; Gustavsen G
Per Med; 2013 Jun; 10(4):387-396. PubMed ID: 29783418
[TBL] [Abstract][Full Text] [Related]
20. Precision reimbursement for precision medicine: the need for patient-level decisions between payers, providers and pharmaceutical companies.
Budhdeo S; Ruhl M; Agapow PM; Sharma N; Moss P
Future Healthc J; 2021 Nov; 8(3):e695-e698. PubMed ID: 34888469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
